Newer Advances in the management of Atopic dermatitis and role of PDE4 inhibitors

Speciality: Dermatology

Description:

A warm welcome to all the medical professionals in this interesting session on Newer Advances in the management of Atopic dermatitis and role of PDE4 inhibitors
Recent advances in the management of atopic dermatitis (AD) have brought significant improvements in treatment, especially for those with moderate to severe forms of the disease. Among these advancements, phosphodiesterase 4 (PDE4) inhibitors, such as crisaborole, have emerged as an effective option for managing mild to moderate AD. PDE4 inhibitors work by targeting the inflammatory pathways involved in AD, reducing the production of pro-inflammatory cytokines, which are central to the disease's flare-ups and symptoms like itching and skin inflammation.
The introduction of PDE4 inhibitors offers several advantages over traditional treatments. Unlike corticosteroids, which are commonly used but have potential side effects with long-term use, PDE4 inhibitors provide a non-steroidal option that is safer for prolonged application, especially on sensitive skin areas like the face. This makes them an attractive choice for patients looking for effective, long-term control of their symptoms without the risks associated with steroids.
Therefore, get an overall knowledge of newer advances in the management of atopic dermatitis and role of PDE4 inhibitors
 

See More Webinars @ Hidoc Webinars